BRPI0506400A - tratamento de tuberculose latente - Google Patents

tratamento de tuberculose latente

Info

Publication number
BRPI0506400A
BRPI0506400A BRPI0506400-7A BRPI0506400A BRPI0506400A BR PI0506400 A BRPI0506400 A BR PI0506400A BR PI0506400 A BRPI0506400 A BR PI0506400A BR PI0506400 A BRPI0506400 A BR PI0506400A
Authority
BR
Brazil
Prior art keywords
alkyl
hydrogen
het
alkyloxy
alkylthio
Prior art date
Application number
BRPI0506400-7A
Other languages
English (en)
Inventor
Koenraad Jozef Lodewij Andries
Anil Koul
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35717702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0506400(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0506400A publication Critical patent/BRPI0506400A/pt
Publication of BRPI0506400A8 publication Critical patent/BRPI0506400A8/pt
Publication of BRPI0506400B1 publication Critical patent/BRPI0506400B1/pt
Publication of BRPI0506400B8 publication Critical patent/BRPI0506400B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"TRATAMENTO DE TUBERCULOSE LATENTE". A presente invenção refere-se ao uso de um composto de fórmula (la) ou (lb) para a fabricação de um medicamento para o tratamento de tuberculose latente, em que o composto de fórmula (a) ou (lb) é um sal farmaceuticamente aceitável, uma amina quaternária, um N-óxido, uma forma tautomérica ou uma forma estereoquimicamente isomérica do mesmo, em que R¬ 1¬ é hidrogênio, halo, haloalquila, ciano, hidróxi, Ar, Het, alquila, alquilóxi, alquiltio, alquiloxialquila, alquiltioalquila, Ar-alquila ou di(Ar)alquila; p é 1, 2, 3 ou 4; R¬ 2¬ é hidrogênio, hidróxi, mercapto, alquilóxi, alquiloxialquilóxi, alquiltio, mono ou di(alquil)amino ou um radical de fórmula ; R¬ 3¬m é alquila, Ar, Ar-alquila, Het ou Het-alquila; q é zero, 1, 2, 3 ou 4; R¬ 4¬ e R¬ 5¬ cada um independentemente, são hidrogênio, alquila ou benzila; ou R¬ 4¬ e R¬ 5¬ podem ser considerados juntos incluindo o N ao qual eles estão ligados; R¬ 6¬ é hidrogênio, halo, haloalquila, hidróxi, Ar, alquila, alquilóxi, alquiltio, alquiloxialquila, alquiltioalquila, Ar-alquila ou di(Ar)alquila; ou dois radicais R¬ 6¬ vizinhos podem ser considerados juntos para formar um radical bivalente -CH=CH-CH=CH-; r é 1, 2, 3, 4 ou 5; R¬ 7¬ é hidrogênio, alquila, Ar ou Het; R¬ 8¬ é hidrogênio ou alquila; R¬ 9¬ é oxo; ou R¬ 8¬ e R¬ 9¬ juntos formam o radical =NCH=CH-.
BRPI0506400A 2004-12-24 2005-12-08 uso de um composto para a fabricação de um medicamento para o tratamento de tuberculose latente BRPI0506400B8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24
EP04078529.7 2004-12-24
EP05105008.6 2005-06-08
EP05105008 2005-06-08

Publications (4)

Publication Number Publication Date
BRPI0506400A true BRPI0506400A (pt) 2006-08-29
BRPI0506400A8 BRPI0506400A8 (pt) 2017-09-12
BRPI0506400B1 BRPI0506400B1 (pt) 2021-04-06
BRPI0506400B8 BRPI0506400B8 (pt) 2021-05-25

Family

ID=35717702

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506400A BRPI0506400B8 (pt) 2004-12-24 2005-12-08 uso de um composto para a fabricação de um medicamento para o tratamento de tuberculose latente

Country Status (30)

Country Link
US (1) US20060142279A1 (pt)
EP (1) EP1830850B1 (pt)
CN (1) CN103142595B (pt)
AP (1) AP2327A (pt)
AR (1) AR051790A1 (pt)
AT (1) ATE501721T1 (pt)
AU (1) AU2005242138B2 (pt)
BR (1) BRPI0506400B8 (pt)
CA (1) CA2529265C (pt)
CR (1) CR9267A (pt)
CY (1) CY1112247T1 (pt)
DE (1) DE602005026984D1 (pt)
DK (1) DK1830850T3 (pt)
EE (1) EE05394B1 (pt)
HR (1) HRP20110392T1 (pt)
IL (1) IL184123A (pt)
LV (1) LV13469B (pt)
ME (1) ME01207B (pt)
MY (1) MY145845A (pt)
NI (1) NI200700146A (pt)
NO (1) NO340376B1 (pt)
NZ (1) NZ555460A (pt)
PA (1) PA8654801A1 (pt)
PL (1) PL1830850T3 (pt)
PT (1) PT1830850E (pt)
RS (1) RS51730B (pt)
SI (1) SI1830850T1 (pt)
TR (1) TR200504892A1 (pt)
TW (1) TWI404535B (pt)
WO (1) WO2006067048A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1527050T3 (da) * 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2752B1 (en) 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
AU2006263882B2 (en) * 2005-06-28 2012-12-13 Janssen Pharmaceutica N.V Quinoline derivatives as antibacterial agents
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
CA2711912A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
US8741917B2 (en) 2009-01-15 2014-06-03 Rutgers, The State University Of New Jersey Benzo [C] phenanthridines as antimicrobial agents
US20120059026A1 (en) 2009-04-30 2012-03-08 University Of Medicine And Dentistry Of New Jersey Antimicrobial agents
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2803890A1 (en) * 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
KR102110355B1 (ko) 2012-04-27 2020-05-14 얀센 파마슈티카 엔.브이. 항균성 퀴놀린 유도체
CA2869453C (en) 2012-04-27 2021-03-02 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
LT3250182T (lt) 2015-01-27 2023-07-10 Janssen Pharmaceutica Nv Dispersinės kompozicijos
WO2017147316A1 (en) 2016-02-25 2017-08-31 Taxis Pharmaceuticals, Inc. Synthetic processes and intermediates
ES2934785T3 (es) * 2016-03-07 2023-02-27 Global Alliance For Tb Drug Development Inc Compuestos antibacterianos y usos de los mismos
RU2629369C1 (ru) * 2016-10-05 2017-08-29 Федеральное Государственное Унитарное Предприятие "Государственный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Химических Реактивов И Особо Чистых Химических Веществ" Четвертичные аммонийные производные 2-аминотиофен-3-карбоксилатов, обладающие противотуберкулезной активностью
US10774093B2 (en) 2017-03-30 2020-09-15 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
JOP20200004B1 (ar) 2017-07-14 2023-09-17 Janssen Pharmaceutica Nv تركيبات طويلة المفعول
RU2661151C1 (ru) * 2017-12-14 2018-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Селективные ингибиторы глицеральдегид-3-фосфатдегидрогеназы микобактерий
WO2020144197A1 (en) 2019-01-09 2020-07-16 Janssen Pharmaceutica Nv Combination in the treatment of nontuberculous mycobacterial diseases
JP2023532982A (ja) 2020-07-09 2023-08-01 ヤンセン ファーマシューティカ エヌ．ベー． 長時間作用型配合物
KR20230038521A (ko) 2020-07-09 2023-03-20 얀센 파마슈티카 엔.브이. 장기 작용 제형
CN116406270A (zh) 2020-11-12 2023-07-07 詹森药业有限公司 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2025068448A1 (en) 2023-09-28 2025-04-03 Janssen Pharmaceutica Nv Atp synthase inhibitors for use in the treatment of non-tuberculosis mycobacteria

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
DK1527050T3 (da) * 2002-07-25 2010-07-19 Janssen Pharmaceutica Nv Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer

Also Published As

Publication number Publication date
DK1830850T3 (da) 2011-06-14
AU2005242138A1 (en) 2006-07-13
WO2006067048A1 (en) 2006-06-29
BRPI0506400B8 (pt) 2021-05-25
CN103142595A (zh) 2013-06-12
CA2529265C (en) 2014-02-11
ME01207B (me) 2013-03-20
EP1830850B1 (en) 2011-03-16
ATE501721T1 (de) 2011-04-15
RS51730B (sr) 2011-10-31
EP1830850A1 (en) 2007-09-12
AU2005242138B2 (en) 2011-05-26
PL1830850T3 (pl) 2011-07-29
CY1112247T1 (el) 2015-12-09
AP2327A (en) 2011-11-25
MY145845A (en) 2012-04-30
NO340376B1 (no) 2017-04-10
TWI404535B (zh) 2013-08-11
BRPI0506400A8 (pt) 2017-09-12
CR9267A (es) 2008-09-09
IL184123A (en) 2011-10-31
SI1830850T1 (sl) 2011-07-29
NZ555460A (en) 2008-11-28
CN103142595B (zh) 2015-05-06
TR200504892A1 (tr) 2010-04-21
PT1830850E (pt) 2011-05-31
HRP20110392T1 (hr) 2011-06-30
EE05394B1 (et) 2011-04-15
US20060142279A1 (en) 2006-06-29
AP2007004054A0 (en) 2007-06-30
EE200500033A (et) 2006-08-15
DE602005026984D1 (de) 2011-04-28
LV13469B (en) 2007-01-20
IL184123A0 (en) 2008-12-29
NI200700146A (es) 2019-05-10
PA8654801A1 (es) 2006-08-03
NO20073823L (no) 2007-07-23
AR051790A1 (es) 2007-02-07
TW200637551A (en) 2006-11-01
BRPI0506400B1 (pt) 2021-04-06
CA2529265A1 (en) 2006-06-24
HK1186125A1 (en) 2014-03-07

Similar Documents

Publication Publication Date Title
BRPI0506400A (pt) tratamento de tuberculose latente
BRPI0614524B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, e o referido composto
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
BRPI0614493B8 (pt) uso de um composto derivado de quinolina, sua combinação, composição farmacêutica, uso da referida combinação, produto, processo para a preparação de um composto e o referido composto
BRPI0506121A (pt) derivados de quinolina como agentes antibacterianos
NO20080499L (no) Kinolinderivater som antibakterielle midler
NO20081068L (no) Kinolinderivater som antibakterielle midler
NO20080501L (no) Kinolinderivater som antibakterielle midler
NO20080481L (no) Kinolinderivater som antibakterielle midler
JO2695B1 (en) Treatment of latent TB
TH80291A (th) การรักษาวัณโรคแฝง

Legal Events

Date Code Title Description
B15K Others concerning applications: alteration of classification

Ipc: C07D 215/22 (2006.01), A61P 31/06 (2006.01), C07D

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 20A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2858 DE 14-10-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.